American Society of Clinical Oncology

SHERPA: White

People

  1. Riely
    Riely
  2. Kris
    Kris
  3. Ladanyi
    Ladanyi
  4. Ginsberg
    Ginsberg
  5. Yu
    Yu
  6. Paik
    Paik
  7. Rusch
    Rusch
  8. Shen
    Shen
  9. D'Angelo
    D'Angelo
  10. Drilon
    Drilon

Groups

  1. Solid Tumor Oncology Division (72)
  2. Thoracic Malignancies Disease Management Team (72)
  3. Thoracic Oncology Service (72)
  4. Thoracic Oncology (46)
  5. Human Oncology and Pathogenesis Program (30)
  6. Thoracic Oncology (26)
  7. Soft Tissue Sarcoma Disease Management Team (17)
  8. Biostatistics Service (12)
  9. Epidemiology and Biostatistics (12)
  10. Body Imaging Service (11)
Search Within
Refine Results
  1. "Gregory Riely"
Formats
  1. Meeting Abstract (50)
  2. Journal Article (22)
Groups
  1. Solid Tumor Oncology Division (72)
  2. Thoracic Malignancies Disease Management Team (72)
  3. Thoracic Oncology Service (72)
  4. Thoracic Oncology (46)
  5. Human Oncology and Pathogenesis Program (30)
  6. Thoracic Oncology (26)

More Groups

People
  1. Gregory Riely (72)
  2. Mark Kris (47)
  3. Marc Ladanyi (27)
  4. Vincent Miller (25)
  5. William Pao (20)
  6. Camelia Sima (15)

More People

Years
  1. 2018 (3)
  2. 2017 (3)
  3. 2015 (12)
  4. 2014 (5)
  5. 2013 (9)
  6. 2012 (2)

More Years

Publications
  1. Journal of Clinical Oncology (69)
  2. American Society of Clinical Oncology Educational Book (2)
  3. Journal of Oncology Practice (1)

Results (72)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial
    Journal Article

    Li, B. T.; Shen, R. L.; Buonocore, D.; Olah, Z. T.; Ni, A.; Ginsberg, M. S.; Ulaner, G. A.; Offin, M.; Feldman, D.; Hembrough, T.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer
    Journal Article

    Arbour, K. C.; Mezquita, L.; Long, N.; Rizvi, H.; Auclin, E.; Ni, A.; Martínez-Bernal, G.; Ferrara, R.; Lai, W. V.; Hendriks, L. E. L.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Molecular determinants of response to anti-programmed cell death (PD)-1 and anti-programmed death-ligand 1 (PD-L1) blockade in patients with non-small-cell lung cancer profiled with targeted next-generation sequencing
    Journal Article

    Rizvi, H.; Sanchez-Vega, F.; La, K.; Chatila, W.; Jonsson, P.; Halpenny, D.; Plodkowski, A.; Long, N.; Sauter, J. L.; Rekhtman, N.; more...
    Journal of Clinical Oncology (2018)

    Fulltext@MSK | Save
  • Case for stopping targeted therapy when lung cancer progresses on treatment in hospice-eligible patients
    Journal Article

    Smith, T. J.; Hanna, N.; Johnson, D.; Baker, S. Jr; Biermann, W. A.; Brahmer, J.; Ellis, P. M.; Giaccone, G.; Hesketh, P. J.; Jaiyesimi, I.; more...
    Journal of Oncology Practice (2017)

    Fulltext@MSK | Save
  • Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology clinical practice guideline update
    Journal Article

    Hanna, N.; Johnson, D.; Temin, S.; Baker, S. Jr; Brahmer, J.; Ellis, P. M.; Giaccone, G.; Hesketh, P. J.; Jaiyesimi, I.; Leighl, N. B.; more...
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Basket trials in oncology: A trade-off between complexity and efficiency
    Journal Article

    Cunanan, K. M.; Gonen, M.; Shen, R.; Hyman, D. M.; Riely, G. J.; Begg, C. B.; Iasonos, A.
    Journal of Clinical Oncology (2017)

    Fulltext@MSK | Save
  • Beyond "second-line" in non-small cell lung cancer: Therapy and supportive care
    Journal Article

    Martins, R. G.; Reynolds, C. H.; Riely, G. J.
    American Society of Clinical Oncology Educational Book (2015)

    Fulltext@MSK | Save
  • A phase I study of twice weekly pulse dose and daily low dose erlotinib as initial treatment for patients (pts) with EGFR-mutant lung cancers
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Reales, D.; Jordan, S.; Rudin, C. M.; Kris, M. G.; Michor, F.; Pao, W.; Riely, G. J.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • First-in-human phase I study of EGF816, a third generation, mutant-selective EGFR tyrosine kinase inhibitor, in advanced non-small cell lung cancer (NSCLC) harboring T790M
    Meeting Abstract

    Tan, D. S. W.; Seto, T.; Leighl, N. B.; Riely, G. J.; Sequist, L. V.; Felip, E.; Wolf, J.; Yang, J. C. H.; Matushansky, I.; Yu, X. L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • A phase 1 study of crizotinib and ganetespib (STA-9090) in ALK positive lung cancers
    Meeting Abstract

    Riely, G. J.; Yu, H. A.; Stephens, D.; Pietanza, M. C.; Smith-Marrone, S.; Fiore, J. J.; Goldstein, M.; Sima, C. S.; Kris, M. G.; Ginsberg, M. S.
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save